Correlation Between Mineralys Therapeutics, and ABVC Biopharma
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and ABVC Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and ABVC Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and ABVC Biopharma, you can compare the effects of market volatilities on Mineralys Therapeutics, and ABVC Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of ABVC Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and ABVC Biopharma.
Diversification Opportunities for Mineralys Therapeutics, and ABVC Biopharma
-0.38 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Mineralys and ABVC is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and ABVC Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ABVC Biopharma and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with ABVC Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ABVC Biopharma has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and ABVC Biopharma go up and down completely randomly.
Pair Corralation between Mineralys Therapeutics, and ABVC Biopharma
Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 1.38 times more return on investment than ABVC Biopharma. However, Mineralys Therapeutics, is 1.38 times more volatile than ABVC Biopharma. It trades about -0.01 of its potential returns per unit of risk. ABVC Biopharma is currently generating about -0.15 per unit of risk. If you would invest 1,350 in Mineralys Therapeutics, Common on September 4, 2024 and sell it today you would lose (63.00) from holding Mineralys Therapeutics, Common or give up 4.67% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Mineralys Therapeutics, Common vs. ABVC Biopharma
Performance |
| Timeline |
| Mineralys Therapeutics, |
| ABVC Biopharma |
Mineralys Therapeutics, and ABVC Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Mineralys Therapeutics, and ABVC Biopharma
The main advantage of trading using opposite Mineralys Therapeutics, and ABVC Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, ABVC Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABVC Biopharma will offset losses from the drop in ABVC Biopharma's long position.| Mineralys Therapeutics, vs. Southwest Airlines | Mineralys Therapeutics, vs. SkyWest | Mineralys Therapeutics, vs. JetBlue Airways Corp | Mineralys Therapeutics, vs. Aegean Airlines SA |
| ABVC Biopharma vs. Indaptus Therapeutics | ABVC Biopharma vs. Pasithea Therapeutics Corp | ABVC Biopharma vs. Forte Biosciences | ABVC Biopharma vs. Aileron Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Complementary Tools
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |